Cargando…

Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer

BACKGROUND: The aim of this study was to investigate the clinical value of liquid biopsy as a primary source for variant analysis in lung cancer. In addition, we sought to characterize liquid biopsy variants and to correlate mutational load to clinical data. METHODS: Circulating cell-free DNA was ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Qvick, Alvida, Stenmark, Bianca, Carlsson, Jessica, Isaksson, Johan, Karlsson, Christina, Helenius, Gisela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254966/
https://www.ncbi.nlm.nih.gov/pubmed/34217228
http://dx.doi.org/10.1186/s10020-021-00331-1
_version_ 1783717811087998976
author Qvick, Alvida
Stenmark, Bianca
Carlsson, Jessica
Isaksson, Johan
Karlsson, Christina
Helenius, Gisela
author_facet Qvick, Alvida
Stenmark, Bianca
Carlsson, Jessica
Isaksson, Johan
Karlsson, Christina
Helenius, Gisela
author_sort Qvick, Alvida
collection PubMed
description BACKGROUND: The aim of this study was to investigate the clinical value of liquid biopsy as a primary source for variant analysis in lung cancer. In addition, we sought to characterize liquid biopsy variants and to correlate mutational load to clinical data. METHODS: Circulating cell-free DNA was extracted from plasma from patients with lung cancer (n = 60) and controls with benign lung disease (n = 16). Variant analysis was performed using the AVENIO ctDNA Surveillance kit and the results were correlated to clinical and variant analysis data from tumor tissue or cytology retrieved from clinical routine diagnostics. RESULTS: There were significantly more variants detected in lung cancer cases compared to controls (p = 0.011), but no difference between the histological subgroups of lung cancer was found (p = 0.465). Furthermore, significantly more variants were detected in patients with stage IIIb–IV disease compared to patients with stage I–IIIa (median 7 vs 4, p = 0.017). Plasma cfDNA mutational load was significantly associated with overall survival (p = 0.010). The association persisted when adjusted for stage and ECOG performance status (HR: 3.64, 95% CI 1.37–9.67, p = 0.009). Agreement between tumor and plasma samples significantly differed with stage; patients with stage IIIb–IV disease showed agreement in 88.2% of the cases with clinically relevant variants, compared to zero cases in stage I–IIIa (p = 0.004). Furthermore, one variant in EGFR, two in KRAS, and one in BRAF were detected in plasma but not in tumor samples. CONCLUSION: This study concludes that in the vast majority of advanced NSCLC patients a reliable variant analysis can be performed using liquid biopsy from plasma. Furthermore, we found that the number of variants in plasma is associated with prognosis, possibly indicating a strategy for closer follow up on this crucial patient group. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10020-021-00331-1.
format Online
Article
Text
id pubmed-8254966
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82549662021-07-06 Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer Qvick, Alvida Stenmark, Bianca Carlsson, Jessica Isaksson, Johan Karlsson, Christina Helenius, Gisela Mol Med Research Article BACKGROUND: The aim of this study was to investigate the clinical value of liquid biopsy as a primary source for variant analysis in lung cancer. In addition, we sought to characterize liquid biopsy variants and to correlate mutational load to clinical data. METHODS: Circulating cell-free DNA was extracted from plasma from patients with lung cancer (n = 60) and controls with benign lung disease (n = 16). Variant analysis was performed using the AVENIO ctDNA Surveillance kit and the results were correlated to clinical and variant analysis data from tumor tissue or cytology retrieved from clinical routine diagnostics. RESULTS: There were significantly more variants detected in lung cancer cases compared to controls (p = 0.011), but no difference between the histological subgroups of lung cancer was found (p = 0.465). Furthermore, significantly more variants were detected in patients with stage IIIb–IV disease compared to patients with stage I–IIIa (median 7 vs 4, p = 0.017). Plasma cfDNA mutational load was significantly associated with overall survival (p = 0.010). The association persisted when adjusted for stage and ECOG performance status (HR: 3.64, 95% CI 1.37–9.67, p = 0.009). Agreement between tumor and plasma samples significantly differed with stage; patients with stage IIIb–IV disease showed agreement in 88.2% of the cases with clinically relevant variants, compared to zero cases in stage I–IIIa (p = 0.004). Furthermore, one variant in EGFR, two in KRAS, and one in BRAF were detected in plasma but not in tumor samples. CONCLUSION: This study concludes that in the vast majority of advanced NSCLC patients a reliable variant analysis can be performed using liquid biopsy from plasma. Furthermore, we found that the number of variants in plasma is associated with prognosis, possibly indicating a strategy for closer follow up on this crucial patient group. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10020-021-00331-1. BioMed Central 2021-07-03 /pmc/articles/PMC8254966/ /pubmed/34217228 http://dx.doi.org/10.1186/s10020-021-00331-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Qvick, Alvida
Stenmark, Bianca
Carlsson, Jessica
Isaksson, Johan
Karlsson, Christina
Helenius, Gisela
Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
title Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
title_full Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
title_fullStr Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
title_full_unstemmed Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
title_short Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
title_sort liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254966/
https://www.ncbi.nlm.nih.gov/pubmed/34217228
http://dx.doi.org/10.1186/s10020-021-00331-1
work_keys_str_mv AT qvickalvida liquidbiopsyasanoptionforpredictivetestingandprognosisinpatientswithlungcancer
AT stenmarkbianca liquidbiopsyasanoptionforpredictivetestingandprognosisinpatientswithlungcancer
AT carlssonjessica liquidbiopsyasanoptionforpredictivetestingandprognosisinpatientswithlungcancer
AT isakssonjohan liquidbiopsyasanoptionforpredictivetestingandprognosisinpatientswithlungcancer
AT karlssonchristina liquidbiopsyasanoptionforpredictivetestingandprognosisinpatientswithlungcancer
AT heleniusgisela liquidbiopsyasanoptionforpredictivetestingandprognosisinpatientswithlungcancer